Use of N-{ [(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl} -3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-N-methyl-3-oxo-1-propanamine and perindopril for treating heart failure
Disclosed is a composition or combination of a compound of formula (II) as in the drawing N- { (7S)-3,4-dimethoxybicyclo [4.2.0]octa-1,3,5-trien-7-yl] methyl} -3 -(7,8-dimethoxy-1 ,2,4,5-tetrahydro-3H-3-benzazepin-3 -yl)-N-methyl-3 -oxo-1-propanamine, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms, and perindopril (2S,3aS,7aS)-1-[(2S)-2-{ [(2S)-1-ethoxy-1-oxopentan-2-yl]amino} propanoyl]-octahydro-1H-indole-2-carboxylic acid, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms, Also disclosed is the use of N- { (7S)-3,4-dimethoxybicyclo [4.2.0]octa-1,3,5-trien-7-yl] methyl} -3 -(7,8 -dimethoxy- 1 ,2,4,5-tetrahydro-3H-3-benzazepin-3 -yl)-N-methyl-3 -oxo-1-propanamine and perindopril for the manufacture of a medicament for the treatment of heart failure with preserved systolic function.
